Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y

Healthpeak Properties (DOC) reported Q2 2025 FFO of $0.46 per share, meeting analyst estimates, though revenues of $694.3 million marginally missed expectations and slightly declined year-over-year. Despite a slight revenue miss and increased interest expenses, the healthcare REIT achieved a 3.5% year-over-year increase in total merger-combined same-store cash net operating income, driven by strong performance in outpatient, lab, and CCRC segments, alongside positive 6% cash-releasing spreads and high tenant retention in its lab and outpatient portfolios. The company reaffirmed its 2025 FFO guidance of $1.81-$1.87 per share and 3-4% same-store NOI growth, while currently holding a Zacks Rank #4 (Sell).

Analysis

Healthpeak Properties' second-quarter 2025 results present a mixed but operationally stable picture. While the company met FFO estimates at $0.46 per share, a marginal year-over-year increase, revenues of $694.3 million slightly missed consensus and declined from the prior year. The core operational strength is evident in the 3.5% year-over-year growth in total merger-combined same-store cash NOI, propelled by robust performance in the CCRC segment (+8.6%) and solid gains in outpatient medical (+3.9%) and lab (+1.5%) segments. This underlying health is further substantiated by strong leasing activity, achieving high tenant retention of 85-87% and positive 6% cash-releasing spreads across both its lab and outpatient portfolios. However, these operational positives were partially offset by a marginal increase in interest expenses, a key headwind for the REIT sector. The company's balance sheet appears managed, with a net debt to adjusted EBITDAre of 5.2x and a recent repayment of $452 million in senior notes. Critically, Healthpeak reaffirmed its full-year 2025 guidance for both FFO per share ($1.81-$1.87) and same-store NOI growth (3-4%), suggesting management confidence despite the external Zacks Rank #4 (Sell) rating.

Key Decisions for Investors

• Investors should weigh the company's solid operational execution, evidenced by 3.5% same-store NOI growth and strong leasing spreads, against the headwinds of a slight revenue decline and rising interest expenses.
• Given the reaffirmed full-year guidance for FFO and NOI, a key focus should be on monitoring future leasing velocity and the company's ability to manage its 5.2x net debt to EBITDAre ratio in the current rate environment.
• The contrast between strong underlying property-level performance and the external Zacks #4 (Sell) rating suggests a neutral or hold position may be appropriate, pending clearer signs of top-line revenue acceleration or a more favorable macro backdrop for REITs.